This week’s topics include a study on ICD programming to reduce inappropriate therapy and mortality, a clinical review of diagnosing and managing supraventricular tachycardia, the Global Burden of Disease Study 2010, and more.

A biotech company has been accused of releasing preliminary and misleading information about a clinical trial. The company, Osiris Therapeutics, is the manufacturer of  a cultured mesenchymal stem cell (MSC) therapy called Prochymal, which is being studied in a phase 2, placebo-controlled trial in post-MI patients. Earlier this week, Osiris issued a press release announcing preliminary results from the trial, in…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

This week, Richard looks at endocarditis and ICDs, more stent wars, stroke prevention in A-Fib, and more.

Two small studies of cardiac stem cells for the treatment of heart failure have shown promise, but ABC News, CBS News, and other media outlets are throwing around words like “medical breakthrough” and “heart failure cure.” ABC News correspondent Richard Besser was so enthusiastic that anchor Diane Sawyer commented that she had never seen him “so excited.”…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Stem cell therapy may help reverse long-term damage after MI, according to a small, preliminary study by a group led by Joshua Hare published in Circulation: Research. Eight patients with LV dysfunction after MI received injections of autologous bone marrow progenitor cells in the LV scar and surrounding area. At one year, as assessed by…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.